Experience of Using Remdesivir in Patients with Novel Coronavirus Infection
Safety and Risk of Pharmacotherapy
; 10(4):365-380, 2022.
Article
in Russian
| EMBASE | ID: covidwho-2244196
ABSTRACT
Timely, effective, and safe antiviral therapy in COVID-19 patients reduces complications, disability and mortality rates. The greatest concern with remdesivir is the risk of drug-induced liver injury, including in patients whose liver function is compromised by COVID-19. The aim of the study was to investigate the efficacy and safety of remdesivir in patients with confirmed SARSCoV-2 infection who had been admitted to an infectious diseases hospital in the Volgograd region in March 2022. Materials and methods:
the authors carried out an open, non-randomised, single-arm study using medical records of 234 patients who had been diagnosed with "U07.1 COVID-19, virus identified” and prescribed remdesivir upon admission. The effectiveness of therapy was evaluated using two criteria the need for oxygen supplementation or ventilatory support, or mortality. The authors conducted the evaluation on days 7, 14, and 28 using the six-point ordinal severity scale by Y. Wang et al. The safety of therapy was assessed on the basis of complaints and changes in laboratory findings.Results:
for the patients prescribed remdesivir at admission, the 7-day mortality rate was 3.0%, the 14-day mortality rate was 5.6%, and the 28-day mortality rate was 7.3%. With the exception of a patient with myocardial infarction, all the patients who had been hospitalised with mild COVID-19 and prescribed remdesivir did not require oxygen therapy and/or transfer to intensive care and were discharged following recovery. The patients with moderate to severe COVID-19 had the 14-day mortality rate of 6.4% and the 28-day mortality rate of 8.6%. 17 patients (7.2%) discontinued remdesivir prematurely for various reasons, including adverse drug reactions. Remdesivir therapy of 5-10 days was associated with an increase in ALT activity by 2.7 ± 0.8 times in 15.9% of patients with mild COVID-19, by 3.8 ± 1.8 times in 20.4% of patients with moderately severe COVID-19, and by 4.8 ± 2.7 times in 24% (12/50) of patients with severe COVID-19. In two patients (0.9%), the increase exceeded 10-fold the upper limit of normal.Conclusions:
the obtained results support recommending remdesivir to patients with mild, moderate and severe COVID-19, including those with moderately elevated baseline activity of hepatic transaminases.
adult; adverse drug reaction; article; assisted ventilation; clinical assessment; communicable disease; coronavirus disease 2019; drug safety; drug therapy; drug-induced liver injury; enzyme activity; female; heart infarction; human; intensive care; major clinical study; male; medical record; mortality; mortality rate; nonhuman; oxygen therapy; randomized controlled trial; Severe acute respiratory syndrome coronavirus 2; side effect; aminotransferase; endogenous compound; remdesivir
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Russian
Journal:
Safety and Risk of Pharmacotherapy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS